--- title: "DRMAW.US (DRMAW.US) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/DRMAW.US/news.md" symbol: "DRMAW.US" name: "DRMAW.US" parent: "https://longbridge.com/en/quote/DRMAW.US.md" datetime: "2026-05-20T14:37:03.693Z" locales: - [en](https://longbridge.com/en/quote/DRMAW.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/DRMAW.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/DRMAW.US/news.md) --- # DRMAW.US (DRMAW.US) — Related News ### [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md) *2026-05-19T19:45:38.000Z* > Analyst Anthony Vendetti from Maxim Group has reiterated a Buy rating on Dermata Therapeutics, maintaining a 12-month pr ### [DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286311130.md) *2026-05-13T20:17:55.000Z* ### [DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286310007.md) *2026-05-13T20:10:58.000Z* ### [10:15 ETDERMA E Reintroduces Itself with a Bold New Direction and Fresh Campaign, "A Lil' Derm Goes a Long Way," Reinforcing Dermatologist-Backed Skincare and New Packaging](https://longbridge.com/en/news/286117015.md) *2026-05-12T14:15:40.000Z* > DERMA E, a dermatologist-recommended skincare brand, announces a bold rebranding with a new campaign titled "A Lil' Derm ### [Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements](https://longbridge.com/en/news/285052237.md) *2026-05-04T09:37:33.000Z* > Dermapharm Holding SE has announced the upcoming publication of its quarterly financial report for Q1 of the 1st half-ye ### [Veradermics Announces Pricing of Upsized Public Offering and Private Placement | MANE Stock News](https://longbridge.com/en/news/284680691.md) *2026-04-29T18:35:37.000Z* > Veradermics Announces Pricing of Upsized Public Offering and Private Placement | MANE Stock News ### [Global Keloid Treatment Market Outlook | North America, Asia Pacific, Europe Lead | Bausch Health, Sciton, Galderma Drive Multi-Modal Dermatology Innovation](https://longbridge.com/en/news/282167578.md) *2026-04-09T09:30:27.000Z* > The global keloid treatment market is evolving into a clinically driven segment, projected to grow from USD 4.29 billion ### [Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause](https://longbridge.com/en/news/282137185.md) *2026-04-09T05:16:05.000Z* > Interim data from two investigator-initiated trials (IITs) supported by Galderma highlight the effectiveness of Sculptra ### [A transaction that made a profit of 182.3 billion in 7 years](https://longbridge.com/en/news/281704989.md) *2026-04-05T08:03:10.000Z* > EQT (EQT Group) set a record for its largest exit in history through the final divestment of the global dermatology comp ### [DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 8-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/280690053.md) *2026-03-26T21:18:20.000Z*